Tumors driven by oncogene amplified extrachromosomal DNA (ecDNA) demonstrate enhanced sensitivity to cell cycle checkpoint kinase 1 (CHK1) inhibition

被引：4
|
作者：
Chowdhry, Sudhir
Milutinovic, Snezana
Tse, Edison
Garcia, Salvador
Perusse, Dean
Ritland, Melissa
Ko, Juyeon
Wilkinson, Deepti
Turner, Kristen
Steffy, Auzon
Plum, Joshua
Ben Norman
Pferdekamper, AnnMarie
Meyer, Todd
Liao, Debbie
Elsdon, Rachelle
Lange, Joshua
Pinkerton, Anthony
Hansen, Ryan
Hassig, Christian
Kasibhatla, Shailaja
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-1626
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1626
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Dissociation of gemcitabine chemosensitization by CHK1 inhibition from cell cycle checkpoint abrogation and aberrant mitotic entry
    Parsels, Leslie A.
    Tanska, Daria M.
    Parsels, Joshua D.
    Zabludoff, Sonya D.
    Cuneo, Kyle C.
    Lawrence, Theodore S.
    Maybaum, Jonathan
    Morgan, Meredith A.
    CELL CYCLE, 2016, 15 (05) : 730 - 739
  • [22] Recovery from DNA damage checkpoint arrest by PP1-mediated inhibition of Chk1
    den Elzen, NR
    O'Connell, MJ
    EMBO JOURNAL, 2004, 23 (04): : 908 - 918
  • [23] Phosphorylation activates Chk1 and is required for checkpoint-mediated cell cycle arrest
    Capasso, H
    Palermo, C
    Wan, SH
    Rao, H
    John, UP
    O'Connell, MJ
    Walworth, NC
    JOURNAL OF CELL SCIENCE, 2002, 115 (23) : 4555 - 4564
  • [24] PVT1 fusion on extrachromosomal DNA (ecDNA) increases oncogene RNA stability and cancer cell growth
    Yi, Hyerim
    Zhang, Shu
    Jones, Matthew G.
    Belk, Julia A.
    Swinderman, Jason
    Shi, Quanming
    Curtis, Ellis J.
    Kanakaveti, Vishnu P.
    Mischel, Paul S.
    Chang, Howard Y.
    MOLECULAR CANCER THERAPEUTICS, 2024, 23 (11)
  • [25] Cdc25 mitotic inducer targeted by Chk1 DNA damage checkpoint kinase
    Furnari, B
    Rhind, N
    Russell, P
    SCIENCE, 1997, 277 (5331) : 1495 - 1497
  • [26] Oral CHK1 inhibitor BBI-355 allows flexibility of dose and schedule with demonstration of monotherapy and combinational antitumor activity in extrachromosomal DNA (ecDNA) driven preclinical models
    Hansen, Ryan J.
    Steffy, Auzon
    Plum, Joshua
    Ardeshiri, Ardalan
    Tse, Edison
    Garcia, Salvador
    Norman, Ben
    Moininazeri, Jafar
    Pferdekamper, AnneMarie
    Holmes, Evan
    Liao, Debbie
    Elsdon, Rachelle
    Lange, Joshua
    Pinkerton, Anthony
    Apuy, Julius
    Chowdhry, Sudhir
    Hassig, Christian
    Kasibhatla, Shailaja
    CANCER RESEARCH, 2024, 84 (06)
  • [27] Downregulation of Cyclin B1 as a potential mechanism of resistance to the cell cycle checkpoint kinase 1 (CHK1) inhibitor, Prexasertib (Prex)
    Nair, J.
    Haynes, B.
    Huang, T. T.
    Lee, J. M.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E116 - E117
  • [28] Regulatory interactions between the checkpoint kinase Chk1 and the proteins of the DNA-dependent protein kinase complex
    Goudelock, DM
    Jiang, KC
    Pereira, E
    Russell, B
    Sanchez, Y
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (32) : 29940 - 29947
  • [29] mTORC1 and DNA-PKcs as novel molecular determinants of sensitivity to Chk1 inhibition
    Massey, Andrew J.
    Stephens, Peter
    Rawlinson, Rebecca
    McGurk, Lauren
    Plummer, Ruth
    Curtin, Nicola J.
    MOLECULAR ONCOLOGY, 2016, 10 (01) : 101 - 112
  • [30] TARGETING MYC/MYCN BY INHIBITION OF CHECKPOINT KINASE 1 (CHK1) SENSITIZES PAEDIATRIC GLIOBLASTOMA (PGBM) CELLS TO TEMOZOLOMIDE
    Nandhabalan, Meera
    Bjerke, Lynn
    Vinci, Mara
    Burford, Anna
    Ingram, Wendy
    Mackay, Alan
    von Bueren, Andre
    Baudis, Michael
    Clarke, Paul
    Collins, Ian
    Workman, Paul
    Jones, Chris
    NEURO-ONCOLOGY, 2014, 16 : 49 - 49
12345